Stopping bisphosphonate therapy in people at risk of bone fractures must be carefully considered
The major rationale for starting anti‐resorptive drug treatment in people with osteoporosis is that the risk of further fractures is 2–4 times and that of mortality 2–3 times as great for someone with a fragility fracture as for other people of the same age. This applies to virtually all fractures, and particularly during the 5 years after a fragility fracture.1,2,3
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
John Eisman has received consulting and research support from Amgen, Eli Lilly, Merck Sharp and Dohme, and Novartis. Christopher White has received consulting and research support from Amgen. None of these companies had any role in the preparation of this Editorial.